Home » Topics » Musculoskeletal, BioWorld Science

Musculoskeletal, BioWorld Science
RSS

New arthritis severity gene id'd

Aug. 1, 2018

European Commission approves adalimumab biosimilar Hyrimoz

July 30, 2018

Bio-Thera Solutions initiates phase I study of tocilizumab biosimilar BAT-1806

July 30, 2018

Meiji Seika Pharma identifies phosphodiesterase PDE4 inhibitors

July 27, 2018

Medivir reports promising topline joint structure outcomes from phase IIa extension study of MIV-711

July 27, 2018

Phase II results of JAK1/2 inhibitor baricitinib for the treatment of systemic lupus erythematosus

July 27, 2018

Corbus plans phase III trial of lenabasum in dermatomyositis

July 26, 2018

Phase IIa study of BT-063 for the treatment of SLE meets primary endpoint

July 23, 2018

Glenmark Pharmaceuticals discloses new RORC antagonists

July 20, 2018

NT-1654 reduces clinical severity of EAMG in rats

July 20, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...